ELAN: Elanco Animal Health Incorporated Stock

by  •  • Comments Off on ELAN: Elanco Animal Health Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,706.43
Enterprise Value ($M) 8,559.43
Book Value ($M) 6,096.00
Book Value / Share 12.28
Price / Book 0.77
NCAV ($M) -3,303.00
NCAV / Share -6.65
Price / NCAV -1.42

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.02
Return on Equity (ROE) 0.06

Liquidity (mrq)
Quick Ratio 1.25
Current Ratio 2.44

Balance Sheet (mrq) ($M)
Current Assets 3,215.00
Assets 12,614.00
Liabilities 6,518.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,439.00
Operating Income 251.00
Net Income 338.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 541.00
Cash from Investing 1,158.00
Cash from Financing -1,492.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-22 13G/A BlackRock, Inc. 4.40 -11.43
03-07 13G/A Fmr Llc 10.00 23.14

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elan
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-02 915,118 3,080,568 29.71
2025-04-30 1,078,488 3,420,207 31.53
2025-04-29 1,899,146 5,657,163 33.57
2025-04-28 1,712,914 4,523,323 37.87

(click for more detail)

Similar Companies
BHVN – Biohaven Ltd. BMY – Bristol-Myers Squibb Company
EBS – Emergent BioSolutions Inc. HYAC – Haymaker Acquisition Corp. 4
JNJ – Johnson & Johnson


Financial data and stock pages provided by
Fintel.io